in vitro transfer of mitochondria from MSCs to cell lines or primary cells, such as cardiomyocytes, endothelial cells, cancer cell, or pulmonary alveolar epithelial cells, has since been extensively documented. 3 All of these studies provide, voluntarily or not, a potential pathophysiological perspective of the endosymbiotic theory of the origin of mitochondria and the eukaryotic cell.
Despite the accumulation of studies demonstrating evidence of mitochondrial transfer, the mechanisms and signals allowing mitochondrial trafficking, transport and entry into the host cell are still unclear. One recurrent hypothesis proposed for mitochondrial transfer is by tunnelling nanotubes from the donor cell to the host cell. In this theory, the mitochondrial Rho-GTPase, Miro1, has been implicated in the movement of the mitochondria along the actin cytoskeleton of the nanotube to the host cell. 4 
dria to a damaged cell, possibly as a rescue mechanism. Whether reduction of mitochondrial transfer by CD38 knockdown is indeed responsible for a decreased post-ischemic neuroplasticity requires further investigation. This novel aspect in intercellular mitochondrial transfer reinforces the concept of a trans-cellular organelle relocalization in response to tissue injury. This concept emerged from a report showing the in vivo transfer of mitochondria from bone marrow MSCs to alveolar epithelial cells following acute lung injury. 5 The mitochondrial transfer increased alveolar ATP synthesis and promoted protective adaptations. The establishment of connexin-43-containing gap junction channels between MSC and alveolar epithelium was a prerequisite to promote mitochondrial transfer and MSC mitochondria containing microvesicle formation. It is unknown if mitochondrial transfer from astrocytes to neurons utilize similar transfer mechanisms or other endocytic processes. Clarification of these mechanisms could provide protective approaches to optimize mitochondria transfer to damaged tissue. From a cardiovascular point of view, the astrocytes-derived mitochondrial vesicles may also have some major functional implications. In the central nervous system, astrocytes are cellular components of the neurovascular units and cover the abluminal surface of the cerebral vessel wall. An increase in luminal blood pressure through mechanosensitive signalling is thought to increase intracellular calcium in astrocytes and the release of vasoactive molecules. 6 Accordingly, one could imagine that blood flow, and thus energy supply, could affect mitochondrial released in the central nervous system as reported in Hayakawa study 1 and also potentially in peripheral tissue. However, it is currently not know if such a mechanism occurs in the heart. One report demonstrated that intravenous injection of autologous mitochondria after a cardiac ischemiareperfusion injury can improve mitochondrial respiration and postischemic myocardial function. 7 Interestingly, adult ventricular cardiomyocytes contain two populations of mitochondria based on their localization, sub-sarcolemmal and intra-myofibrillar mitochondria. Among the differences between these two populations, connexin-43 is present solely in sub-sarcolemmal mitochondria and its expression level has been associated with a cardioprotective effect against ischemia. 8 A possible link between the specific presence of connexin-43 sub-sarcolemmal mitochondria and connexin-43 associated transcellular mitochondrial transfer requires examination. In parallel, the possibility of mitochondrial transfer in vivo between native cells in the context of cardiac ischemic injury raises several important questions: can resident non-cardiomyocytes cells release mitochondrial vesicles within the heart under ischemic injury? Could a paracrine mitochondrial transfer constitute an adaptive mechanism for ischemic injury and participate in pre-or post-conditioning? May mitochondrial transfer also affect sympathetic neurons plasticity within the heart? Could mitochondrial vesicular release provide a future biomarker of myocardial infarction? The biological implications of cardiac mitochondrial transfer are clearly and potentially broad.
To some extent, targeted transcellular mitochondrial transfer to rescue ischemic organs may sound somehow esoteric but mitochondrial dysfunction is associated with a broad range of pathophysiological conditions, and strategies to improve mitochondrial function, especially in cardiovascular diseases, are very few. An improved understanding of the mechanisms that orchestrate mitochondrial transfer from a donor cell to a host cell, from the trigger signals to the molecular processes allowing mitochondrial entry and integration, will open new opportunities to boost and stabilize mitochondria against tissue injuries.
